Allakos Inc (ALLK)

Overview News Price History Option Chain Discussions Forecast

Allakos Inc stock is currently priced at $1.04, with a 24-hour trading volume of 59,443. It has seen a -1.89% decreased in the last 24 hours and a -16.80% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.07 pivot point. If it approaches the $1.02 support level, significant changes may occur.

Allakos Inc Stock (ALLK) Financials Data

Allakos Inc (ALLK) Net Income 2024

ALLK net income (TTM) was -$166.14 million for the quarter ending September 30, 2023, a +55.26% increase year-over-year.

Allakos Inc (ALLK) Cash Flow 2024

ALLK recorded a free cash flow (TTM) of -$139.91 million for the quarter ending September 30, 2023, a +56.55% increase year-over-year.

Allakos Inc (ALLK) Earnings per Share 2024

ALLK earnings per share (TTM) was -$1.92 for the quarter ending September 30, 2023, a +71.60% growth year-over-year.

Allakos Inc Stock (ALLK) Latest News

Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions

Zacks Investment Research

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

GlobeNewswire Inc.

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

GlobeNewswire Inc.

Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update

Zacks Investment Research

Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug

Zacks Investment Research

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.

Upgrade	Jefferies: Hold → Buy	May-12-23
Initiated	Piper Sandler: Overweight	Mar-07-23
Downgrade	SMBC Nikko: Neutral → Underperform	Sep-12-22
Downgrade	BofA Securities: Buy → Underperform	Dec-22-21
Downgrade	Cowen: Outperform → Market Perform	Dec-22-21
Downgrade	Jefferies: Buy → Hold	Dec-22-21
Downgrade	SVB Leerink: Outperform → Mkt Perform	Dec-22-21
Downgrade	William Blair: Outperform → Mkt Perform	Dec-22-21
Initiated	Morgan Stanley: Equal-Weight	Aug-26-21
Initiated	Cowen: Outperform	Jul-15-21
Initiated	H.C. Wainwright: Buy	May-18-21
Initiated	Cantor Fitzgerald: Overweight	Feb-24-21
Initiated	BofA Securities: Buy	Jan-15-21
Initiated	SVB Leerink: Outperform	Dec-21-20
Initiated	Barclays: Underweight	Feb-27-20
Resumed	Goldman: Neutral	Feb-04-20
Initiated	Goldman: Neutral	Aug-13-18
Initiated	Jefferies: Buy	Aug-13-18
Initiated	William Blair: Outperform	Aug-13-18